Search Autoimmune Association
Share this article
Hrl Cropped E

AARDA’s Statement on HHS Approval of Notice of Benefit and Payment Parameters Rule

Statement from Randall Rutta, President and CEO, Autoimmune Association on HHS Approval of Notice of Benefit and Payment Parameters Rule

Washington, D.C. (May 8, 2020) – Randall Rutta, President and CEO of the Autoimmune Association, released the following statement on HHS’ decision to move forward with a rule that allows health insurers not to count copay assistance toward out-of-pocket maximum limits for medications:

“On behalf of millions of patients living with autoimmune and chronic diseases, their families, and the healthcare professionals who care for them, we are deeply disappointed by the Administration’s finalization of the 2021 Notice of Benefit and Payment Parameters. Specifically, allowing health insurers to not count copay assistance support from drug manufacturers towards patient annual cost-sharing limitations is harmful at a time when so many people are struggling personally and financially. We should be doing everything we can to ensure that patients have affordable access to the medicines they need. This move is counterproductive for millions of patients and families.

“Autoimmune Association opposed the proposed reversal earlier this year, urging HHS to retain the copay assistance policy that helps patients cover out-of-pocket costs for medicines, allowing them the ability to maintain stability in health conditions, avoid exacerbations or relapses, and achieve continuity of care. We strongly believe now, as we did then, that patients should not be punished for accessing such assistance.

“We urge the Administration to reconsider its decision and recognize the reversal will cause unnecessary hardships and risks to health and wellness. We will continue to work with CMS and policymakers to highlight the importance of changing course on this rule.

“Now more than ever, those dealing with serious, rare, and chronic conditions need assurance that they can access necessary medications without unnecessary costs. Refusing to count copay assistance from drug manufacturers toward out-of-pocket cost limits will result in major health setbacks and unmanageable financial burden for millions. In the midst of a global pandemic, patients deserve better from Washington.”

Share this article

Join our email list

Receive the latest blog articles, news, and more right to your inbox!

Related articles you might be interested in

Am Addisons Disease Celiac Mom Story

Addison’s Disease & Celiac Mom Story: “The Autoimmune Snowball”

I was 32 years old.  I had just survived a miserable pregnancy and rough delivery, but instead of gaining my strength back and...
Am Addisons Disease

Addison’s Disease: Overview of Antibodies & Genetic Links

Addison’s disease, also known as primary adrenal insufficiency, is an endocrine condition involving destruction of parts of the adrenal gland (which sits atop...
Am Addisons Disease And Pregnancy

Addison’s Disease and Pregnancy

What are some implications for pregnancy with Addison’s disease? Among the many autoimmune diseases, Addison’s stands out as one with an often delayed...

Find more resources on autoimmunity

Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.

NEW WEBSITE:

Welcome, and thank you for visiting our brand-new website!

We’re excited to be launching the site with new content and features created to provide you with the information you are seeking.

Learn More